sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 73 NHL / PRIMA


News
1. Overview
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms


return to top

News


No news


1. Overview



Summary

A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera?) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy


Status

closed


Type of study

Prospective randomized Phase III study


Target number of patients

480


Current number of patients

18


Date of activation

20-Jan-2006


Date closed

27-Mar-2007


Approved by

CKTO: CKTO 2005-14, 8 September 2005
METC: METC UMCU, 6 July 2005, METc 05/118-E


2. Patient eligibility criteria



Inclusion criteria

Histologically confirmed follicular lymphoma grade 1, 2 or 3a.
Patients previously untreated.
Patients with at least one of the following symptoms requiring initiation of treatment:
a. Bulky disease at study entry according to the GELF criteria: nodal or extranodal mass > 7cm in its greater diameter
b. B symptoms
c. Elevated serum LDH or b2-microglobulin
d. involvement of at least 3 nodal sites (each with a diameter greater than 3 cm) symptomatic splenic enlargement
e. compressive syndrome
f. pleural/peritoneal effusion
Age must be >= 18 years.
Performance status <= 2 on the ECOG scale (see appendix E).
Adequate hematological function within 28 days prior to registration (unless those abnormalities are related to lymphoma extension), this includes:
a. Hemoglobin >= 8.0 g/dl (5.0 mmol/L)
b. Absolute neutrophil count (ANC) >= 1.5 10 ^9/L
c. Platelet count >= 100 10 ^9/L
Women are not breast feeding, are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter.
Having previously signed a written informed consent form.

Patient Eligibility Criteria for randomization:
All lesions reported in the on-study form have been re-evaluated.
Patient must have reached a PR, CRu or CR. (According to appendix C)
Patient should have received all full doses of induction treatment, excepted planned modifications.


Exclusion criteria

Transformation to high-grade lymphoma (secondary to low-grade follicular lymphoma).
Grade 3b follicular lymphoma.
Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis).
Patients regularly taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to <= 20 mg/day prednisone.
Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer.
Major surgery (excluding lymph node biopsy) within 28 days prior to registration.
Poor renal function: Serum creatinine > 2.0 mg/dl (197 micromol/L),
Poor hepatic function: total bilirubin > 2.0 mg/dl (34 micromol/L), AST (SGOT) > 3 x the upper limit of normal unless these abnormalities are related to lymphoma.
Known HIV infection or active HBV or HCV infection.
Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease). Judgment is up to the investigator.
Life expectancy < 6 months
Known sensitivity or allergy to murine products
Treatment within a clinical trial within 30 days prior to trial entry
Adult patient under tutelage.

Exclusion Criteria for randomization:
Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease). Judgment is up to the investigator.
Patient with delayed chemotherapy courses for more than 2 weeks (> 14 days).


3. Registration (& randomization) of patients



Registration

Central registration at the HOVON Data Center:
Erasmus MC Cancer Institute, Clinical Trial Center (Hs-423)
P.O. Box 2040
NL-3000 CA Rotterdam
Phone number.: +31.10.7041560 (working days 9.00-17.00)
Fax number.....: +31.10.7041028
TOP address...: http://www.hdc.hovon.nl/top


Registration criteria

The following information will be requested:



Protocol number
Institution name
Name of caller/responsible investigator
Patient's initials or code
Patient's hospital record number (optional)
Sex
Date of birth
Eligibility criteria


4. Participating parties



Principal Investigator(s)

Prof. Dr. A. Hagenbeek (AMC)


Statistician(s)

Dhr. W.L.J. van Putten (Erasmus MC - Daniel)


Trial Manager(s)

Mw. M.C.J. Abrahamse - Testroote (Erasmus MC - Daniel)


Central Data Manager(s)

GELA randomization center (Hôpital Saint Louis-Centre Hayem)


Monitor - Study Specific

Dhr. J. de Neijs (Trialogic)


Other functions

Reviewer - Pathology - Mw. Dr. D. de Jong (VUMC)


Principal investigator

Pr. Gilles Salles


Coordinating investigator(s)

A. Hagenbeek (a.hagenbeek@amc.uva.nl)


Statistician(s)

W.L.J. van Putten (w.vanputten@erasmusmc.nl)


Trial manager

M. Abrahamse-Testroote (m.testroote@erasmusmc.nl)
(back-up: p.cornelisse@erasmusmc.nl)


Central data management

M. Abrahamse-Testroote (m.testroote@erasmusmc.nl)
(back-up: p.cornelisse@erasmusmc.nl)


5. Participating sites



Site
Included patients *
NL-Amsterdam-AMC
4
NL-Amsterdam-Antoni van Leeuwenhoek ZH
3
NL-Amsterdam-VUMC
3
NL-Den Haag-Hagaziekenhuis, locatie Leyweg
2
NL-Den Helder-Noordwest Ziekenhuisgroep
0
NL-Hoorn-Esperanz - Westfriesgasthuis
0
NL-Leidschendam-MC Haaglanden, Antoniushove
1
NL-Nieuwegein-Antonius Ziekenhuis
1
NL-Nijmegen-Radboudumc
1
NL-Rotterdam-Erasmus MC - Daniel
1
Show 4 more...
* Please note that if TOP is not used to register patients for a study, the number of patients shown is zero.

6. Instruction videos



7. Download documentation / forms


 Protocol



return to top